Sign up
Quantellect · Analysts · Analyst Profile
Q Score Rank#339 of 449

Robert Wasserman

Benchmark · Equity Research Analyst
EstablishedRating since 2020No new ratings since Aug 2025

Analyst rating accuracy & track record

Robert Wasserman is an equity research analyst at Benchmark. Quantellect has scored 64 of their stock calls across 17 companies. Their picks beat their sector 38% of the time over the next 12 months, and their price targets were reached 40% of the time within a year.

Win % vs sector
38%
PT Hit % (12mo)
40%
Avg sector-excess
−13.5%
Scored calls
64
Tickers
17
Tier
Established

Track record

Quantellect has scored 64 of Robert Wasserman's stock calls across 17 companies, dating back to 2020. Their rated stocks beat their own sector 38% of the time over the next 12 months. On a typical call, a Wasserman pick returned −13.5% more than its sector over the following year.

Of the scored calls, 64 were bullish (Buy). Most of their coverage sits in Healthcare. Every number on this page is an estimate from our own data. It is for education only and is not investment advice.

Coverage & ratings

Ratings & price targets

StockRatingPrice targetRated12-mo vs sectorPT hit
INTSIntensity Therapeutics, Inc. Common stock
Buy$1.50Aug 2025−65.3%Hit
NEPHNephros Inc
Buy$5.00Aug 2025−22.2%Hit
BLFSBioLife Solutions Inc
Buy$30.00Aug 2025+15.0%Hit
EBSEmergent Biosolutions Inc
Buy$12.00Aug 2025−76.2%Hit
EBSEmergent Biosolutions Inc
Buy$12.00Aug 2025−76.2%Hit
TECHBio-Techne Corp
Buy$75.00Aug 2025+15.3%Miss
HYFTImmunoPrecise Antibodies Ltd.
Buy$3.00Jul 2025−46.9%Hit
TECHBio-Techne Corp
Buy$75.00Jun 2025−8.5%Miss
ANEBAnebulo Pharmaceuticals Inc
Buy$3.00May 2025−76.0%Hit
ANEBAnebulo Pharmaceuticals Inc
Buy$3.00May 2025−76.0%Hit
KMDAKamada
Buy$15.00May 2025+3.5%Miss
OABIOmniAb Inc.
Buy$6.00May 2025+19.6%Miss
TECHBio-Techne Corp
Buy$75.00May 2025−12.7%Miss
XOMAXOMA Royalty Corporation
Buy$35.00Apr 2025+65.5%Hit
KMDAKamada
Buy$15.00Mar 2025+18.9%Miss
OABIOmniAb Inc.
Buy$6.00Mar 2025−31.7%Miss
LGNDLigand Pharmaceuticals Incorporated
Buy$135.00Dec 2024+60.9%Hit
ANEBAnebulo Pharmaceuticals Inc
Buy$8.00Nov 2024+42.8%Miss
OABIOmniAb Inc.
Buy$8.00Nov 2024−68.7%Miss
NEPHNephros Inc
Buy$5.00Nov 2024+173.8%Hit
EBSEmergent Biosolutions Inc
Buy$12.00Nov 2024−12.7%Hit
ANEBAnebulo Pharmaceuticals Inc
Buy$8.00Oct 2024+26.2%Miss
OABIOmniAb Inc.
Buy$8.00Aug 2024−41.6%Miss
EBSEmergent Biosolutions Inc
Buy$8.00Aug 2024−14.9%Hit
EBSEmergent Biosolutions Inc
Buy$8.00Aug 2024+33.7%Hit
INTSIntensity Therapeutics, Inc. Common stock
Buy$12.00Jul 2024−86.2%Miss
EBSEmergent Biosolutions Inc
Buy$8.00Jul 2024−7.3%Hit
EBSEmergent Biosolutions Inc
Buy$8.00Jul 2024−1.8%Hit
EBSEmergent Biosolutions Inc
Buy$8.00Jun 2024+5.5%Hit
EBSEmergent Biosolutions Inc
Buy$8.00Jun 2024+4.9%Hit
EBSEmergent Biosolutions Inc
Buy$8.00Jun 2024+3.6%Hit
PRLBProto Labs Inc
Buy$45.00May 2024+3.4%Hit
INTSIntensity Therapeutics, Inc. Common stock
Buy$12.00May 2024−83.8%Miss
NEPHNephros Inc
Buy$5.00May 2024+3.5%Miss
OABIOmniAb Inc.
Buy$8.00May 2024−56.0%Miss
CDXSCodexis Inc
Buy$9.00May 2024−28.8%Miss
EBSEmergent Biosolutions Inc
Buy$5.00Apr 2024+113.0%Hit
OABIOmniAb Inc.
Buy$8.00Mar 2024−55.1%Miss
INTSIntensity Therapeutics, Inc. Common stock
Buy$12.00Mar 2024−64.9%Miss
NEPHNephros Inc
Buy$5.00Mar 2024−36.1%Miss
ATHEAlterity Therapeutics Ltd
Buy$4.00Mar 2024+114.6%Hit
EBSEmergent Biosolutions Inc
Buy$5.00Mar 2024+110.9%Hit
PCSAProcessa Pharmaceuticals Inc
Buy$4.00Mar 2024−81.3%Miss
CDXSCodexis Inc
Buy$9.00Feb 2024−37.4%Miss
ABCLAbcellera Biologics Inc
BuyFeb 2024−38.4%
INTSIntensity Therapeutics, Inc. Common stock
Buy$12.00Nov 2023+14.8%Miss
OABIOmniAb Inc.
Buy$8.00Nov 2023−28.8%Miss
ANEBAnebulo Pharmaceuticals Inc
Buy$8.00Oct 2023−59.0%Miss
CDXSCodexis Inc
Buy$9.00Sep 2023+37.7%Miss
ABCLAbcellera Biologics Inc
Buy$12.00Aug 2023−73.8%Miss
Prev1
Go to

Robert Wasserman: analyst track record FAQ

Is Robert Wasserman a good stock analyst?

Yes, by track record. Robert Wasserman ranks number 339 of 449 of the analysts Quantellect scores, with a Q Score of 10 out of 100. Past results do not guarantee future ones.

What is Robert Wasserman's win rate?

Robert Wasserman's win rate is 38%. Across 64 scored calls, their rated stocks beat their sector 38% of the time over the next 12 months. On a typical call they returned −13.5% more than the sector.

What stocks and sectors does Robert Wasserman cover?

Robert Wasserman covers 17 companies, with the most coverage in Healthcare. See the ratings table above for every scored call and its outcome.

Are Robert Wasserman's price targets accurate?

Robert Wasserman's price targets are reached within 12 months 40% of the time. The base rate across all analysts Quantellect tracks is about 43 percent.

How accurate are Wall Street analyst price targets?

Most analyst price targets are not reached on schedule. Across every target Quantellect scores, the stock reaches the target within 12 months only about 43 percent of the time, which is why it helps to compare hit rates analyst by analyst.

Should I follow Robert Wasserman's stock ratings?

Their track record is strong, but no analyst is right every time. Follow the long-term track record rather than any single rating, size your positions to your own risk, and treat this as research, not investment advice.

How does Quantellect score analyst accuracy?

Quantellect scores every rating on real prices. We enter at the closing price on or after the call date, with no look-ahead, then measure the 12-month return above the stock's sector ETF and check whether the price target was reached. Scores are pulled toward the population average and corrected for testing thousands of analysts at once, so they reflect repeatable skill rather than luck.

How does Robert Wasserman rank among Wall Street analysts?

Robert Wasserman ranks number 339 of 449 by Q Score. We rank analysts by their realized 12-month sector-excess return and require a minimum number of calls so a few lucky picks cannot reach the top.

Browse the full analyst leaderboardHow analyst accuracy is scored

Every score, Win %, PT Hit % and rank is an estimate Quantellect calculates from its own data and may not be 100% accurate or complete. Returns are measured in excess of each rated stock's own sector over the 12 months after each call. Past performance does not guarantee future results, and nothing here is a recommendation to buy or sell any security.